Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$20 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-4.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.7
Industry P/E
--
EV/EBITDA
0.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-13.4
Face value
--
Shares outstanding
13,481,070
CFO
$-356.43 Mln
EBITDA
$-429.85 Mln
Net Profit
$-442.67 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
| -44.6 | -30.3 | -44.6 | -82.9 | -62.5 | -63.6 | -62.1 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
| -73.5 | -80.8 | 282.6 | -78.2 | -83.6 | -68.2 | -15.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
1.6 | 20.5 | 1.0 | -36.1 | -3,662.6 | -412.5 | -- | 4.7 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome... proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 Read more
CEO, President & Director
Mr. Stephen R. Brady J.D., LLM
CEO, President & Director
Mr. Stephen R. Brady J.D., LLM
Headquarters
Brisbane, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Tempest Therapeutics Inc (TPST) is $1.59 (NASDAQ) as of 02-Apr-2026 19:10 EDT. Tempest Therapeutics Inc (TPST) has given a return of -62.5% in the last 3 years.
Since, TTM earnings of Tempest Therapeutics Inc (TPST) is negative, P/E ratio is not available.
The P/B ratio of Tempest Therapeutics Inc (TPST) is 4.69 times as on 31-Mar-2026, a 18 premium to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.04
|
0.09
|
|
2023
|
-0.15
|
0.16
|
|
2022
|
-0.03
|
0.06
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Tempest Therapeutics Inc (TPST) are Rs 12.23 and Rs 1.50 as of 05-Apr-2026.
Tempest Therapeutics Inc (TPST) has a market capitalisation of $ 20 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Tempest Therapeutics Inc (TPST), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.